The Synthesis of Cycloserine and market price analysis
2023
- 17Usage
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Usage17
- Abstract Views17
Artifact Description
Tuberculosis, caused by Mycobacterium tuberculosis, a bacterial pathogen that attacks macrophages by puncturing the membrane resulting in cell apoptosis, has been known to be drug-resistant, leaving many patients at risk for a worsening condition. Cycloserine is a second-line treatment for Multi-drug resistant tuberculosis (MDR-TB) in which the cyclic analog to D-alanine targets alanine racemase and D-alanine ligase, blocking the formation of the bacterial cell wall. After an excessive price hike in 2015, initially a 2100% increase and currently a 110% increase, many could not afford treatment. This study drives to synthesize cycloserine for less than the listed price sold. This process is completed by multistep synthesis of cycloserine and then cost analysis. Described in the study are the results and cost analysis.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know